Abstract
[Display omitted]
•A contribution to drug repurposing using deep learning and optimization is proposed.•A novel deep learning model is developed to predict Drug-Target binding affinities.•The proposed model integrates a Convolutional Neural Network on the top of a BiLSTM.•The Hyperparameters of the model are set using a Differential Evolution algorithm.•The Differential Evolution-based learning framework outperformed baseline methods.
The identification of drug-target interactions (DTIs) is an important process in drug repositioning and drug discovery. However, it is very expensive and time-consuming to determine all possible DTIs with experimental approaches. Most existing machine learning-based methods formulate the DTIs prediction problem as a binary classification problem. Nevertheless, the lack of experimentally validated negative samples results in imbalanced class distribution within the datasets, which may have a negative influence on the DTI prediction performance. Casting DTI prediction task as a regression problem seems an interesting alternative to avoid this issue especially with the recent increase in protein structural data and DTI datasets. Within this context, a twofold contribution is described in this paper. First, we propose a novel deep learning model for predicting drug-target binding affinities called “Convolution Neural Network with Attention-based bidirectional Long Short-Term Memory network” (CNN-AbiLSTM), which combines a CNN with an attention-based biLSTM. Second, building a powerful hybrid CNN-AbiLSTM model can be highly complicated and requires a suitable setting of the model’s hyperparameters. To handle this problem, we propose an evolutionary algorithm-based framework more specifically a Differential Evolution (DE) algorithm to find the optimal configuration of the proposed model. Experimental results show that the proposed DE-based CNN-AbiLSTM model achieves better performance compared with baseline methods.